JP2022502508A5 - - Google Patents
Info
- Publication number
- JP2022502508A5 JP2022502508A5 JP2021542087A JP2021542087A JP2022502508A5 JP 2022502508 A5 JP2022502508 A5 JP 2022502508A5 JP 2021542087 A JP2021542087 A JP 2021542087A JP 2021542087 A JP2021542087 A JP 2021542087A JP 2022502508 A5 JP2022502508 A5 JP 2022502508A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antibody
- ptcl
- cell lymphoma
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739631P | 2018-10-01 | 2018-10-01 | |
| US62/739,631 | 2018-10-01 | ||
| PCT/US2019/054107 WO2020072519A1 (en) | 2018-10-01 | 2019-10-01 | Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502508A JP2022502508A (ja) | 2022-01-11 |
| JP2022502508A5 true JP2022502508A5 (https=) | 2022-10-11 |
Family
ID=68296746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542087A Pending JP2022502508A (ja) | 2018-10-01 | 2019-10-01 | 抗ｃｄ３０抗体薬物複合体療法を使用して末梢性ｔ細胞リンパ腫を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200102399A1 (https=) |
| EP (1) | EP3860658A1 (https=) |
| JP (1) | JP2022502508A (https=) |
| KR (1) | KR20210069679A (https=) |
| CN (1) | CN113613678A (https=) |
| AU (1) | AU2019355875A1 (https=) |
| CA (1) | CA3114922A1 (https=) |
| IL (1) | IL281920A (https=) |
| MX (1) | MX2021003734A (https=) |
| SG (1) | SG11202103342QA (https=) |
| WO (1) | WO2020072519A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CA3183602A1 (en) * | 2020-05-13 | 2021-11-18 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
| JP7652918B2 (ja) | 2021-03-01 | 2025-03-27 | ナントバイオ，インコーポレイテッド | 抗ｃｄ３０モノクローナル抗体及びキメラ抗原受容体 |
| WO2024145637A2 (en) * | 2022-12-30 | 2024-07-04 | The Regents Of The University Of Colorado, A Body Corporate | Immunotoxin-based targeted therapy for cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| WO2010081004A1 (en) | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| CN110022938A (zh) * | 2016-11-14 | 2019-07-16 | 千禧制药公司 | 抗cd30抗体药物缀合物的非成年人给药 |
| US20220226439A1 (en) * | 2017-11-01 | 2022-07-21 | Seagen Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
-
2019
- 2019-10-01 US US16/589,914 patent/US20200102399A1/en active Pending
- 2019-10-01 WO PCT/US2019/054107 patent/WO2020072519A1/en not_active Ceased
- 2019-10-01 CN CN201980071250.5A patent/CN113613678A/zh active Pending
- 2019-10-01 CA CA3114922A patent/CA3114922A1/en active Pending
- 2019-10-01 EP EP19791017.7A patent/EP3860658A1/en active Pending
- 2019-10-01 JP JP2021542087A patent/JP2022502508A/ja active Pending
- 2019-10-01 AU AU2019355875A patent/AU2019355875A1/en active Pending
- 2019-10-01 MX MX2021003734A patent/MX2021003734A/es unknown
- 2019-10-01 KR KR1020217012841A patent/KR20210069679A/ko not_active Ceased
- 2019-10-01 SG SG11202103342QA patent/SG11202103342QA/en unknown
-
2021
- 2021-03-31 IL IL281920A patent/IL281920A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502508A5 (https=) | ||
| AU2020222295B2 (en) | Pharmaceutical combination comprising TNO155 and a PD-1 inhibitor | |
| CN101686971B (zh) | 用于治疗多发性骨髓瘤的药物产品及其用途 | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| CN103118706B (zh) | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl | |
| JP2023508496A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2021501776A5 (https=) | ||
| Tuscano et al. | Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts | |
| JP2021523233A5 (https=) | ||
| WO2025061123A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| JP2021523158A5 (https=) | ||
| CA2156579A1 (en) | Method of treating vascular leak syndrome | |
| Cheng et al. | Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors | |
| JP2023500697A5 (https=) | ||
| IL315350A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| JP2022164894A (ja) | 非成人のヒトに対する抗ｃｄ３０抗体－薬物コンジュゲートの投与 | |
| JP2021501800A5 (https=) | ||
| JPH01502909A (ja) | 免疫毒素による人間の治療における免疫抑制 | |
| TWI832866B (zh) | 醫藥組合 | |
| Goldsmith et al. | Bispecific antibodies for the treatment of multiple myeloma | |
| Richardson et al. | Antibody drug conjugates in the treatment of epithelial ovarian cancer | |
| WO2024199405A1 (zh) | 含抗cd20抗体药物偶联物的药物组合在制备治疗nhl的药物中的用途 |